Increased risk of leukemia among sickle cell disease patients in California

Blood

Volumn 130, Issue 13, 2017, Pages 1597-1599

  Brunson, Ann ^a   Keegan, Theresa H M ^a   Bang, Heejung ^a,b   Mahajan, Anjlee ^a   Paulukonis, Susan ^c   Wun, Ted ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PUBLIC HEALTH INSTITUTE   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOID LEUKEMIA; BREAST CANCER; CALIFORNIA; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LETTER; LEUKEMIA; MALE GENITAL TRACT CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SICKLE CELL ANEMIA; SOLID MALIGNANT NEOPLASM; ADULT; BREAST TUMOR; CELL TRANSFORMATION; COMORBIDITY; FEMALE; INCIDENCE; INFLAMMATION; MALE; MALE GENITAL TRACT TUMOR; MIDDLE AGED; NEOPLASM; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK;

ADULT; ANEMIA, SICKLE CELL; BREAST NEOPLASMS; CALIFORNIA; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; INCIDENCE; INFLAMMATION; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK;

EID: 85030030865     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-783233     Document Type: Letter

References (25)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23): 1639-1644.
2. Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep. 2016;131(2):367-375.
3. Chen L, Zhuang M, Shah HQ, Lin JH. Chronic myelogenous leukemia in sickle cell anemia. Arch Pathol Lab Med. 2005;129(3):423-424.
4. Moschovi M, Psychou F, Menegas D, Tsangaris GT, Tzortzatou-Stathopoulou F, Nicolaidou P. Hodgkin’s disease in a child with sickle cell disease treated with hydroxyurea [published correction appears in Pediatr Hematol Oncol. 2007; 24(8):651]. Pediatr Hematol Oncol. 2001;18(6):371-376.
5. Stricker RB, Linker CA, Crowley TJ, Embury SH. Hematologic malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol. 1986;21(2):223-230.
6. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133(11):925-926.
7. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003;74(4):249-253.
8. Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ. Risk of individual malignant neoplasms in patients with sickle cell disease: English National Record Linkage Study. J R Soc Med. 2016;109(8):303-309.
9. Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017;178(2):319-326.
10. Adesina O, Brunson A, Keegan THM, Wun T. Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv. 2017;1(16):1287-1295.
11. Paulukonis ST, Harris WT, Coates TD, et al. Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer. 2014;61(12):2271-2276.
12. Eisenbrown K, Nimmer M, Brousseau DC. The accuracy of using ICD-9-CM codes to determine genotype and fever status of patients with sickle cell disease. Pediatr Blood Cancer. 2015;62(5):924-925.
13. California Cancer Registry. California Cancer Reporting System Standards: Abstracting and Coding Procedures for Hospitals. Vol I. Sacramento, CA: California Department of Public Health; 2015.
14. Breslow NE, Day NE. Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
15. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3(3):255-260.
16. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12): 939-955.
17. Charache S, Terrin ML, Moore RD, et al; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
18. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000; 106(3):337-338.
19. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013-2037.
20. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584-596.
21. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605-1621.
22. Chung WS, Lin CL, Lin CL, Kao CH. Thalassaemia and risk of cancer: a population-based cohort study. J Epidemiol Community Health. 2015;69(11): 1066-1070.
23. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008;100(14):996-1002.
24. Terman DS, Viglianti BL, Zennadi R, et al. Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. PLoS One. 2013;8(1):e52543.
25. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.